Spironolactone and furosemide are prescribed together in cirrhosis because they target different parts of the kidney, and neither works well enough alone. Cirrhosis causes the body to retain massive amounts of sodium and water, leading to fluid buildup in the abdomen called ascites. Spironolactone blocks the hormone driving most of that sodium retention, while furosemide adds extra fluid removal and helps balance out potassium levels. Together, they clear ascites more effectively and more safely than either drug on its own.
How Cirrhosis Tricks the Body Into Hoarding Sodium
To understand why this drug combination works, you need to understand what cirrhosis does to the kidneys, even when the kidneys themselves are healthy. As liver scarring worsens, blood pressure drops in the main arteries because blood pools in the vessels around the gut. The body interprets this as low blood volume and responds by activating every fluid-retention system it has.
The most important of these is the renin-angiotensin-aldosterone system. Aldosterone is a hormone that tells the kidneys to hold onto sodium, and water follows sodium. In cirrhosis, aldosterone levels climb far above normal, a state called secondary hyperaldosteronism. The sympathetic nervous system also ramps up, triggering even more sodium reabsorption further upstream in the kidney. The result is a body that relentlessly holds onto salt and water, pushing fluid through blood vessel walls and into the abdominal cavity.
Why Spironolactone Is the Foundation
Spironolactone works by blocking aldosterone in the final stretch of the kidney’s filtration system, the distal tubule and collecting duct. Since hyperaldosteronism is the central driver of sodium retention in cirrhosis, blocking it directly addresses the root problem. Clinical experience consistently shows that spironolactone alone is more effective at clearing ascites than furosemide alone.
European liver guidelines are explicit on this point: aldosterone antagonists are “more effective than loop diuretics in the management of ascites and are the diuretics of choice.” For a first episode of moderate ascites, spironolactone by itself, starting at 100 mg daily and increased as needed up to 400 mg, is a reasonable first step.
Why Furosemide Alone Falls Short
Furosemide is a loop diuretic, meaning it blocks sodium reabsorption in the loop of Henle, a section of the kidney that sits upstream from where aldosterone acts. In most medical situations, loop diuretics are the most powerful fluid removers available. Cirrhosis is the exception.
The problem is straightforward. Furosemide prevents sodium from being absorbed in the loop of Henle, so more sodium flows downstream. But with sky-high aldosterone levels, the distal tubule simply reabsorbs all that extra sodium before it can leave the body. In effect, furosemide moves the problem from one part of the kidney to another without solving it. Studies of patients who didn’t respond to furosemide found they had the highest levels of renin and aldosterone. On top of that, cirrhosis alters how furosemide reaches the kidney: less of the drug gets secreted into the kidney’s interior, and increased sodium uptake in the proximal tubule means less fluid even reaches the loop of Henle for furosemide to act on.
What the Combination Achieves
When spironolactone and furosemide are used together, they block sodium reabsorption at two different points along the kidney tubule. Spironolactone shuts down the aldosterone-driven reabsorption downstream, which finally allows furosemide’s upstream blockade to translate into real sodium and water loss. The combination produces a stronger diuretic effect than either drug alone.
There’s a second, equally important benefit: potassium balance. Furosemide causes the body to lose potassium in urine, which can drive levels dangerously low. Low potassium in cirrhosis is particularly risky because it can trigger hepatic encephalopathy, a condition where toxins accumulate in the brain and cause confusion or worse. Spironolactone does the opposite. It spares potassium, tending to raise levels. Used together, the two drugs largely cancel out each other’s effect on potassium, keeping levels in a safer range. Before potassium-sparing diuretics became standard, low potassium from diuretics was a common cause of encephalopathy in cirrhosis patients.
The 100:40 Dosing Ratio
Major liver societies recommend starting the combination at 100 mg of spironolactone and 40 mg of furosemide daily. This 5:2 ratio is maintained as doses increase, so if you need more diuresis, both medications go up proportionally. The maximum doses are 400 mg of spironolactone and 160 mg of furosemide per day.
The rationale for the 5:2 ratio is potassium equilibrium. At this proportion, spironolactone’s potassium-sparing effect roughly offsets furosemide’s potassium-wasting effect. Though the supporting data for this exact ratio is more tradition than rigorous trial evidence, it has remained the accepted standard for decades because it works well in practice.
Weight Loss Targets During Treatment
The goal of combination diuretic therapy isn’t just to reduce fluid. It’s to reduce it at a safe pace. If you have peripheral edema (swelling in the legs and ankles) along with ascites, the target is weight loss of up to 1 kg (about 2.2 pounds) per day. Once the leg swelling resolves but abdominal fluid remains, the safe limit drops to about 0.5 kg (roughly 1 pound) per day.
This distinction matters because edema fluid can be mobilized quickly from tissue back into the bloodstream, but ascites fluid moves more slowly. Pushing diuretics too hard once the edema is gone can drain the bloodstream faster than the abdominal fluid can refill it, leading to dehydration of the circulatory system even while liters of fluid still sit in the abdomen.
Risks of Over-Diuresis
Removing too much fluid too fast is one of the most common complications of diuretic therapy in cirrhosis. Roughly 25% of over-diuresed patients develop significant blood volume depletion, which can cause kidney impairment. About 26% develop hepatic encephalopathy, and 28% develop dangerously low sodium levels (hyponatremia).
High potassium is the complication that most often limits spironolactone use specifically. Since cirrhosis patients already have impaired kidney function and altered hormone levels, potassium can climb quickly. Gynecomastia (breast tissue growth in men) and gastrointestinal side effects are also more common with the spironolactone-furosemide combination than with alternative potassium-sparing diuretics.
Regular blood work monitoring sodium, potassium, and kidney function is essential throughout treatment. If sodium drops below 121 to 125 and kidney function worsens, diuretics are typically stopped and fluids given. If sodium falls to 120 or below, diuretics are stopped regardless of other values.
Why Sodium Restriction Still Matters
Diuretics work by blocking sodium reabsorption in the kidneys, but they can only remove what the kidneys are processing. If sodium intake is high, even the combination of spironolactone and furosemide may not create enough of a deficit to clear ascites. Most guidelines recommend limiting dietary sodium to about 2,000 mg per day (roughly 5 grams of table salt) to give diuretics their best chance of working. Without sodium restriction, a significant portion of patients will be classified as diuretic-resistant when the real problem is dietary intake overwhelming the drugs’ capacity.